Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
Sunosi (solriamfetol) is an oral selective dopamine and norepinephrine reuptake inhibitor indicated for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea.
Polivy (polituzumab-vedotin-piiq) is an intravenously administered CD79b-directed antibody-drug conjugate indicated in combination with a rituximab product and bendamustine for adult patients with relapsed/refractory diffuse large B-cell lymphoma after at least 2 prior therapies.
Spravato is a drug-device combination consisting of esketamine for intranasal administration intended for the treatment of treatment resistant depression. Spravato is the s-enantiomer of ketamine, an FDA-approved general anesthetic agent. Spravato is a more potent anesthetic than ketamine, but has a more rapid metabolism. Spravato has been designated a Schedule III controlled substance, and may be subject to abuse and diversion.
Brolucizumab is a humanized single-chain antibody fragment designed to inhibit activation of vascular endothelial growth factor (VEGF) receptors. Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular age-related macular degeneration.
Lasmiditan is a first-in-class oral medication that selectively targets serotonin 5-HT1F receptors. This novel molecular class of migraine therapy is believed to penetrate the central nervous system and block trigeminal neuron activation, thereby inhibiting the acute migraine pathway. Due to its low affinity for 5-HT1B receptors, lasmiditan lacks vasoconstrictive properties commonly seen with other migraine medications. Lasmiditan is being developed as an acute therapy for migraine headache to address significant unmet needs in patients with cardiovascular risk factors, those with stable cardiovascular disease, or patients who respond poorly to their current treatment.